Testing TH07 against a placebo for androgenic alopecia
Official title: Androgenic Alopecia TH07 Clinical Trial
Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.
- Phase 3
- 4 groups
- One site, in Vancouver
- Recruiting
Interventions (4)
- Medication
TH07
TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day
- Medication
TH07
* TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day * Placebo; topical solution; once a day
- Medication
Minoxidil 5% Topical Solution
Minoxidil 5%; topical solution; twice a day
- Other intervention
Placebo
Placebo; topical solution; twice a day
Canadian Sites (1)
1 of 1 recruiting
- Recruiting
YVR Aesthetic Training and Study Centre.
Vancouver, British Columbia
Eligibility Criteria
See who this study is looking for32 criteria
The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.
Inclusion
- +Males, 18 to 49 years of age on the date of enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →.
- +Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
- +Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
- +Not administered any systemic or topical treatment for AGA during the last 90 days.
- +Willing to comply with the following restrictions for the duration of trial participation:
- +Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
- +Hair dyes, hair texturizers, relaxers etc.
- +Any new vitamins or nutritional supplements that are currently not being administered.
- +Tattooing in the trial target area.
- +Blood donations.
- +OTC hair restorers.
- +Participation in any other drug or device trials during the course of this trial.
- +Note: However, the following shall be permissible:
- +Non-medicated \& anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.
- +Current regimen (if any) of vitamins and nutritional supplements.
- +Willing and able to provide written informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more → for participation in the trial and to comply with all trial requirements.
- +Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.
- +Do not expose your pregnant partner to your hands/skin where the drug might be present.
Exclusion
- −Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more → may affect the outcome of trial.
- −History of scalp treatment including though not limited to any of the following:
- −Hair weaving.
- −Laser or light therapy on the scalp in the last 6 months.
- −Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.
- −Any other surgical treatment for hair loss
- −Any of the following hair styles:
- −Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
- −Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
- −History or likelihood of use of any of the specified medicines.
- −History or clinical diagnosis of any of the specified medical conditions.
- −Participation in any investigational or marketed drug or device trial in the last 90 days prior to screeningScreeningThe checks done before joining, to see whether a study fits.Read more → for this trial.
- −Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → in the trial.
- −Hair transplant or extension surgery.
In plain language
Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.
What this study is
This study is testing a treatment for a condition.
Phase 3Phase 3A large study comparing a treatment against the current standard.Read more → — a large study comparing this against the current standard, usually across many hospitals.
From the trial registry
Built from these fields:
- designModule.designInfo.primaryPurpose
- designModule.phases
Who receives what
There are 4 groups in this study.
Groups A and B receive TH07.
Registry label: A: Arm A · B: Arm B
Group C, the comparison group, receives Minoxidil 5% Topical Solution.
Registry label: C: Arm C
Group D, the placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group, receives Placebo.
Registry label: D: Arm D
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].label
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
How the study is run
Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.
You, the study team, and the people analysing the results would all be kept unaware of which group you are in until the study ends.
From the trial registry
Built from these fields:
- designModule.designInfo.allocation
- designModule.designInfo.maskingInfo.masking
Is there a placebo?
One group receives a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → — a dummy treatment with no active medicine in it.
One group receives an existing treatment, so the two can be compared.
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for
The study lists an age range of 18 years to 49 years.
The study lists male participants only.
The study does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.
From the trial registry
Built from these fields:
- eligibilityModule.minimumAge
- eligibilityModule.maximumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How big and how long
The study aims to enrol about 420 people.
The study is currently expected to finish around April 2028.
The main measurement is taken over: BaselineBaselineYour starting measurements, taken before treatment begins.Read more → and week 24.
From the trial registry
Built from these fields:
- designModule.enrollmentInfo.count
- statusModule.completionDateStruct.date
- outcomesModule.primaryOutcomes[].timeFrame
What the study measures
Non-vellus hair count — measured over BaselineBaselineYour starting measurements, taken before treatment begins.Read more → and week 24.
From the trial registry
Built from these fields:
- outcomesModule.primaryOutcomes[].measure
- outcomesModule.primaryOutcomes[].timeFrame
Source: NCT07435012 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.
Not medical advice. What do these terms mean?
What is being tested — in plain terms
About TH07Drug
TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About TH07Drug
* TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day * Placebo; topical solution; once a day
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About Minoxidil 5% Topical SolutionDrug
Minoxidil 5%; topical solution; twice a day
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About PlaceboOther
Placebo; topical solution; twice a day
From the trial registry — its own words, unedited.
What a other is here: An intervention the registry did not place in another category.
Read the full explanation → · in clinical review
Common questions
Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.
Am I eligible for this trial?
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.
What the study lists: an age range of 18 years to 49 years.
The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.
The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.maximumAge
- eligibilityModule.eligibilityCriteria
Is there a placebo?
Yes. This study includes a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group — a dummy treatment with no active medicine in it.
One group receives an existing treatment so the two can be compared.
From the trial registry
- armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?
You, the study team, and the people analysing the results would all be kept unaware of which group you are in until the study ends.
Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.
From the trial registry
- designModule.designInfo.maskingInfo.masking
- designModule.designInfo.allocation
Who can join?
The study lists an age range of 18 years to 49 years.
It lists male participants only.
It does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.maximumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How long would this take?
The study's main measurement is taken over: BaselineBaselineYour starting measurements, taken before treatment begins.Read more → and week 24.
The study as a whole is currently expected to finish around 2028-04.
How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.
From the trial registry
- outcomesModule.primaryOutcomes[].timeFrame
- statusModule.completionDateStruct.date
How many people are taking part?
The study aims to enrol about 420 people.
From the trial registry
- designModule.enrollmentInfo.count
Where is this happening?
This study lists one location: Vancouver, British Columbia, Canada.
Sites can open and close during a study, so confirm with the team before travelling.
From the trial registry
- trial_locations
About This Trial
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.
Think this trial might be right for you?
Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.
See if this trial could fit youThis page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.